Dimension Therapeutics (DMTX) Stock Price, News & Analysis

Company Overview

Dimension Therapeutics, Inc. is a gene therapy company. The Company is focused on discovering and developing therapeutic products for people living with rare diseases associated with the liver and caused by genetic mutations. It has programs for hemophilia B, hemophilia A, ornithine transcarbamylase (OTC) deficiency, and glycogen storage disease type Ia (GSDIa). The Company's gene therapy product candidates and programs are designed to provide a functional copy of an abnormal or missing gene using the advanced adeno-associated virus (AAV)-based vector delivery technology. DTX101 is the Company's lead gene therapy product candidate designed to deliver Factor IX (FIX), gene expression in patients with hemophilia B. DTX201 is its Factor VIII (FVIII) gene therapy program for the treatment of hemophilia A. DTX301 is its gene therapy product candidate designed for the treatment of patients with OTC deficiency. DTX401 is its gene therapy program for the treatment of patients with GSDIa.

Key Stats

• Today's Range: $5.95 to $5.95
• 50-Day Range: N/A
• 52-Week Range: $1.05 to $6.10
• Volume: N/A
• Average Volume: 150,214 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DMTX Stock Analysis - Frequently Asked Questions

How were Dimension Therapeutics' earnings last quarter?

Dimension Therapeutics, Inc. (NASDAQ:DMTX) announced its earnings results on Monday, November, 6th. The biotechnology company reported ($0.68) earnings per share for the quarter, missing the consensus estimate of ($0.48) by $0.20. The biotechnology company had revenue of $4.48 million for the quarter.

What other stocks do shareholders of Dimension Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Dimension Therapeutics investors own include Aldeyra Therapeutics (ALDX), Allena Pharmaceuticals (ALNA), Ampliphi Biosciences (APHB), Aquinox Pharmaceuticals (AQXP), Bellicum Pharmaceuticals (BLCM) and Can-Fite BioPharma (CANF).

Company Calendar

• Last Earnings: 11/06/2017
• Today: 8/15/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: N/A
• Industry: N/A
• Sub-Industry: N/A
• Current Symbol: NASDAQ:DMTX
• CIK: 1592288
• Web: dimensiontx.com
• Phone: +1-617-4010011
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A